Snapshot

The Emergency Use Authorization (EUA) of Medical Products pathway has been developed by the of Ghana.

This pathway can be used where Allopathic Medicines, Biological Products, including Vaccines and Medical Devices..

This pathway accelerates the regulatory review process.

It is an abridged review (a reliance pathway).

The timelines for processing an EUA will depend on the product profile; the existence, if any, of pending applications for the product; the nature of the emergency; and other relevant factors. Although the length of time required for action will vary, the FDA recognizes that it is likely that, in an emergency situation that is occurring or believed imminent, a request for consideration for an EUA will be acted upon within 15 working days.